Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Gene editing or genome editing is the insertion, deletion or replacement of DNA at a specific site in the genome of an organism or cell. It is usually achieved in the lab using engineered nucleases also known as molecular scissors. There are several recognised gene editing methods. Editing the genome can be achieved using engineered nucleases such as CRISPR-Cas9, ZFNs or TALENs, viral systems such as rAAV and transposons. It has been used effectively in a wide variety of tissues and organisms through cell line engineering in human cancer cells and IPSCs, and in mammalian model organisms such as knockout mice and rats.
The global genome editing market is witnessing significant growth owing to factors such as surge in the number of genomics projects, high prevalence of infectious diseases, increasing production of genetically modified crops and growing application areas of genomics. Recent advances in genome editing technologies have substantially improved the ability to make precise changes in the genomes of eukaryotic cells. Programmable nucleases, particularly the CRISPR/Cas system, are already revolutionizing the ability to interrogate the function of the genome and can potentially be used clinically to correct or introduce genetic mutations to treat diseases that are refractory to traditional therapies. Furthermore, use of genome editing in specialized/personalized medicine would further provide significant growth opportunities to this market. However, the market is hampered by dearth of trained professionals and adverse public perception of genetic research.
The report analyses the global genome editing market based on technology, application, end user and geography.
Based on technology, the market is categorized into CRISPR, transcription activator-like effector nuclease (TALEN), zinc finger nucleases (ZFNs), antisense and other technologies including PiggyBac, Flp-In, Adenine Base Editor (ABE), and Jump-In. CRISPR-based methods are particularly promising owing to their relative efficiency, low cost; and ease of use, and the prospect of making edits at multiple sites in the genome in a single procedure.
The genome editing market has applications in cell line engineering, genetic engineering and other including diagnostics and therapeutics. In genetic engineering, they are widely used in animal and plant genetic engineering. Genome editing has been used to modify human blood cells to treat conditions including leukaemia and AIDS. It could also potentially be used to treat other infections and simple genetic conditions such as muscular dystrophy and haemophilia.
Several end users of this market are pharmaceutical & biotechnology companies, academic & research institutes and contract research organizations. Targeted nucleases have provided researchers with the ability to manipulate virtually any genomic sequence, enabling the facile creation of isogenic cell lines and animal models for the study of human disease, and promoting exciting new possibilities for human gene therapy.
By geography, the global genome editing market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world regions which includes Latin America, and Middle East & Africa. North America accounted for the market largest share in 2018. Development of gene therapy in the U.S., rising availability of research grants and funding are the key growth drivers of this market in this region. Moreover, the Asia Pacific is expected to show lucrative growth during the forecast period due to expansion of research infrastructure, economic development and intensifying public awareness levels.
The leading market players of the global genome editing market are Merck, Horizon Discovery Group, Genscript, Sangamo Biosciences, Integrated DNA Technologies, Lonza, New England Biolabs, Origene Technologies, Transposagen Biopharmaceuticals, Editas Medicine and CRISPR Therapeutics.
The global genome editing market is segmented based on technology, application, end user and geography. Based on technology, the market is categorized into CRISPR, transcription activator-like effector nuclease (TALEN), zinc finger nucleases (ZFNs), antisense and other technologies including PiggyBac, Flp-In, Adenine Base Editor (ADE), and Jump-In. CRISPR-based methods are particularly promising owing to their relative efficiency, low cost; and ease of use, and the prospect of making edits at multiple sites in the genome in a single procedure.
The genome editing market has applications in cell line engineering, genetic engineering and other including diagnostics and therapeutics. In genetic engineering, they are widely used in animal and plant genetic engineering. Genome editing has been used to modify human blood cells to treat conditions including leukaemia and AIDS.
Numerous end users of this market are pharmaceutical & biotechnology companies, academic & research institutes and contract research organizations. Targeted nucleases have provided researchers with the ability to manipulate virtually any genomic sequence, enabling the facile creation of isogenic cell lines and animal models for the study of human disease, and promoting exciting new possibilities for human gene therapy.
By geography, the global genome editing market is studied across the countries of key regions such as, North America, Europe, Asia Pacific and rest of the world regions which includes Latin America, and Middle East & Africa. North America accounted for the market largest share in 2018. Development of gene therapy in the U.S., rising availability of research grants and funding are the key growth drivers of this market in this region.
Why to buy this report:
